You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1
Yoon Mee Yang
 + 2045 word(s) 2045 2021-12-20 06:55:39 |
2 format correction
Peter Tang
 Meta information modification 2045 2021-12-21 04:22:52 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Yang, Y.M. Hepatokines and Non-Alcoholic Fatty Liver Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/17360 (accessed on 14 July 2025).
Yang YM. Hepatokines and Non-Alcoholic Fatty Liver Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/17360. Accessed July 14, 2025.
Yang, Yoon Mee. "Hepatokines and Non-Alcoholic Fatty Liver Disease" Encyclopedia, https://encyclopedia.pub/entry/17360 (accessed July 14, 2025).
Yang, Y.M. (2021, December 21). Hepatokines and Non-Alcoholic Fatty Liver Disease. In Encyclopedia. https://encyclopedia.pub/entry/17360
Yang, Yoon Mee. "Hepatokines and Non-Alcoholic Fatty Liver Disease." Encyclopedia. Web. 21 December, 2021.
Hepatokines and Non-Alcoholic Fatty Liver Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines9121903

Hepatokines are hormone-like proteins secreted by hepatocytes, and a number of these have been associated with extra-hepatic metabolic regulation. Mounting evidence has revealed that the secretory profiles of hepatokines are significantly altered in non-alcoholic fatty liver disease (NAFLD), the most common hepatic manifestation, which frequently precedes other metabolic disorders, including insulin resistance and type 2 diabetes. 

inter-organ communication NAFLD organokine liver metabolism ANGPTL Fetuin

1. Introduction

The global prevalence of obesity has been increasing over several decades, reaching epidemic levels, and thus, raising serious public health concerns [1]. Obesity greatly increases the risk of metabolic syndrome, including insulin resistance, type 2 diabetes, fatty liver disease, cardiovascular disease, and neurodegenerative conditions, thereby significantly contributing to greater morbidity and mortality [1]. Moreover, obesity-induced chronic inflammation, particularly in the liver, adipose tissue, and skeletal muscle, plays a crucial role in the development of local and systemic insulin resistance, simultaneously inducing a range of metabolic disturbances in multiple organs via inter-organ crosstalk [2][3]. Given the concurrent detrimental influence of obesity on various organs, obesity-driven metabolic disorders are largely attributed to dysregulated multi-directional interactions between organ metabolism. In other words, inter-organ communication via autocrine, paracrine, and endocrine signals regulates systemic energy homeostasis, which can be disturbed by a disequilibrium between energy intake and expenditure (e.g., obesity, hepatic steatosis, etc.).
Non-alcoholic fatty liver disease (NAFLD) refers to the spectrum of chronic liver disease progression in the absence of excessive alcohol consumption, ranging from simple hepatic steatosis to severe pathological conditions, including non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma [4][5][6][7]. Hepatic steatosis is characterized by the accumulation of ectopic lipids in hepatocytes by more than 5% of total liver mass, exhibiting mostly benign and/or mild clinical symptoms. However, this becomes problematic after developing NASH with the signs of hepatocellular damage, inflammation and fibrotic changes, favoring its progression towards more debilitating conditions. In parallel, emerging evidence has also revealed that patients with NAFLD have greater susceptibility to various infectious diseases, including bacterial pneumonia, Helicobacter pylori infection, urinary tract infection, Clostridium difficile colitis, and coronavirus disease 2019 (COVID-19) in close association with low-grade chronic inflammation, impaired innate immunity, and/or vitamin D deficiency [8][9]. NAFLD serves as an early hepatic manifestation that is primarily responsible for the progression of a variety of metabolic disorders [4][5][6][7], implying the multifactorial features of NAFLD and its close link with other comorbidities. Given the heterogenous pathogenesis of NAFLD and its increasing prevalence, leading international societies of hepatology have recently proposed new nomenclature ‘metabolic dysfunction-associated fatty liver disease’ (MAFLD) in the replacement of NAFLD, emphasizing more on its function in metabolic dysregulation, in order to better reflect the current knowledge, as well as its diverse etiologies of metabolic liver disease [10][11].
Recent advances in comprehensive genetic, transcriptomic, and proteomic technologies have provided insights into the role of the liver as an endocrine organ central to metabolism. Moreover, growing evidence has revealed that the liver mediates metabolic regulation through the release of various secretory factors, including hepatokines [12][13][14][15]. Hepatokines are hormone-like proteins primarily secreted by hepatocytes, with the hepatokine secretory profile known to be markedly disturbed in NAFLD. In fact, NAFLD frequently precedes dysfunction in other organs during the pathogenesis of systemic metabolic diseases. Therefore, it is highly likely that altered hepatokine secretion at NAFLD onset will significantly impair the inter-organ signaling crosstalk, which may trigger the progression of complex and multifaceted metabolic dysregulation.

2. Role of the Liver in Metabolism under Normal Physiology

The liver contributes to the maintenance of systemic metabolism by controlling complex pathways that coordinate nutrient intake and energy expenditure. Blood flows into the liver from the heart through the hepatic artery (~25% of total blood volume) or from the gastrointestinal tract via the portal vein (~75%), with most of the nutrients (e.g., glucose and lipids) absorbed in the intestines which are delivered prior to their entry into systemic circulation. These anatomical and structural features enable the liver to sense and promptly respond to changes in nutrient availability [16][17].
The liver serves as a key regulator of glucose metabolism by orchestrating hepatic glucose production and glycogen storage. In a postprandial state, hepatic glucose uptake is upregulated in response to elevated plasma glucose and insulin levels. Then, the absorbed glucose is stored in the liver as glycogen or is utilized for fatty acid synthesis (i.e., de novo lipogenesis). Under the influence of insulin secreted in response to elevated blood glucose, hepatic glucose production and glycogenolysis are suppressed in order to normalize blood glucose concentrations [13][14]. During the fasting state, the liver upregulates blood glucose levels by stimulating hepatic glucose production and glycogen breakdown via transcriptional and non-transcriptional mechanisms [13][18][19], thus increasing the supply of glucose as a major energy source to non-hepatic peripheral tissues (e.g., brain, adipose tissue, skeletal muscle). The liver also plays a key role in lipid metabolism in response to nutrient availability, as well as insulin. Following a meal, insulin facilitates hepatic fatty acid uptake, the synthesis and storage of triglycerides (TG) via the utilization of dietary fatty acids, and promotes de novo lipogenesis in the liver [20], favoring long-term lipid storage. However, under fasting, wherein glucose availability is low, the liver carries out lipid oxidation and acutely produces ketone bodies, which serve as an alternative fuel source for non-hepatic tissues in order to meet energy demands [20][21]. As the liver encounters repetitive fasting-feeding transitions throughout the life cycle of living organisms, the hepatic regulation of metabolism, including energy production, expenditure, storage, and redistribution, is critical for maintaining systemic energy homeostasis under normal physiology.

3. Overview of Hepatokines

The liver regulates physiology and metabolism via the production and secretion of various plasma proteins, including albumin, coagulation factors, complement factors, transport proteins, and other factors [14]. Although the liver has long been recognized as a secretory organ, recent advances in mass spectrometry-based quantitative proteomics have enabled researchers to identify ~10,200 proteins produced in the human liver [22], with up to 40% of hepatic transcripts encoding secretory proteins [23]. Similarly, quantitative analysis of the mouse liver and plasma proteome identified 7099 and 4727 proteins, respectively, with ~25% of these overlapping with plasma proteins, suggestive of their secretion [12][24]. As mentioned above, the liver is directly connected to systemic circulation, receiving a substantial amount of blood from the heart and gastrointestinal tract, exchanging nutrients and other substances within the sinusoids, and then draining blood via the hepatic vein and inferior vena cava towards the heart for recirculation throughout the body [14]. Considering its secretory capacity as an endocrine organ, it is plausible to expect that the liver plays a fundamental role in inter-organ crosstalk through the release of secretory proteins, including hepatokines.
Analogous to adipose tissue-derived adipokines and skeletal muscle-derived myokines, hepatokines are a class of organokines, meaning a group of secretory proteins that are exclusively produced by the parenchymal cell type of respective tissue. The significance of hepatokines in the regulation of various biological processes in autocrine, paracrine, and endocrine fashion has been recently highlighted [13][25]. Given the functional features of hepatocytes, which constitute ~80% of the volume and ~70% of the total cell number within the whole liver, several studies have shown that normal mouse hepatocytes release more than 500 secretory proteins, which may or may not contain an N-terminal secretory peptide [12][26]. Since emerging evidence has demonstrated that factors secreted from hepatocytes actively mediate metabolic regulation between the liver and other organs, hepatokines have drawn increasing attention due to their capacity for metabolic regulation, making them novel targets for the modulation of energy homeostasis and the treatment of metabolic disorders [12][13][14][15]. In this review, we summarized target organs or cells of important hepatokines and their biological functions (Table 1).
Table 1. Target organs or cells of hepatokines and their biological functions.

Hepatokines

Target Organs or Cells

Biological Functions

Reference

ANGPTL3

WAT, muscle, liver

Suppressed LPL and endothelial lipase

Increased plasma TG and FFA

Increased VLDL-TG secretion (liver)

Increased uptake of VLDL-TGs (WAT)

Decreased glucose uptake (WAT)

Promoted lipogenesis and inflammatory response (liver)

[15][27][28][29][30][31][32][33]

ANGPTL4

WAT, vascular endothelial cells

Inhibited LPL activity

Increased plasma TG levels

NAFLDIncreased adipocyte lipolysis

Suppressed hepatic glucose production

[15][34][35][36][37][38][39]

ANGPTL6

skeletal muscle, WAT, liver

Enhanced insulin signaling (skeletal muscle)

Inhibited gluconeogenic pathway (liver)

Increased mitochondrial oxygen consumption (WAT)

[40][41][42][43]

ANGPTL8

hepatocytes, adipocytes

Improved insulin signaling and suppressed gluconeogenic gene expression (liver)

Suppressed lipolysis (hepatocyte, adipocyte)

Promoted lipogenesis (liver)

[44][45][46][47][48]

Fetuin-A

liver, WAT, skeletal muscle, monocytes

Blocked insulin signaling through inhibition of insulin receptor tyrosine kinase (liver, WAT, skeletal muscle)

Provoked inflammatory response (monocytes, adipocytes)

Inhibited adiponectin production

[13][15][49][50][51][52][53][54][55]

Fetuin-B

hepatocytes, myotubes

Induced insulin resistance (hepatocytes, myotubes)

Promoted lipogenesis (hepatocytes)

[26][56]

FGF21

WAT/BAT, liver, skeletal muscle, pancreas, CNS

Promoted glucose uptake (adipocytes)

Stimulated thermogenesis (BAT)

Enhanced insulin secretion (pancreatic β cells)

Increased fatty acid oxidation and insulin sensitivity (liver, skeletal muscle)

Reduced NAFLD

Decreased VLDL uptake and lipogenesis (liver)

Decreased alcohol and sugar intake

Increased energy expenditure and decreased body weight (CNS)

[57][58][59][60]

Selenoprotein P

liver, skeletal muscle

Inhibited hepatic glucose production

Decreased glucose uptake (skeletal muscle)

[12][61][62][63][64]

LECT2

liver, skeletal muscle

Increased M1/M2 ratio and hepatic inflammation (liver)

Development of insulin resistance (skeletal muscle)

Promoted lipid accumulation (liver)

[65][66]

Follistatin

pituitary, skeletal muscle, liver, skeletal muscle, WAT, BAT

Inhibition of FSH production (pituitary)

Suppressed skeletal muscle growth via antagonizing myostatin

Promoted insulin resistance (liver, skeletal muscle, WAT)

Increased glucose and FFA uptake after exercise training (skeletal muscle)

Induced differentiation of brown adipocytes

Promoted thermogenesis (BAT)

[14][15][67][68][69][70][71]

Hepassocin

liver, skeletal muscle, WAT

Promoted insulin resistance

NAFLD

Adipogenesis (WAT)

[72][73][74][75]

RBP4

various peripheral tissues including retina

Increased lipolysis in adipocytes

Promoted hepatic mitochondrial dysfunction and hepatic steatosisSerum RBP4 levels were associated with insulin resistance and components of metabolic syndrome in humans

Depending on the source of RBP4 (hepatocytes or adipocytes), the effect of RBP4 is controversial.

- RBP4 treatment increased PEPCK (liver) and impaired insulin signaling (muscle and adipocytes).

- No effect of liver-secreted RBP4 on glucose homeostasis in mice

[76][77][78][79][80][81][82]

SMOC1

liver, skeletal muscle, etc.

Improved glycemic control via inhibiting gluconeogenesis and glucose output (liver)

[83]

GDF15

adipose tissue, skeletal muscle, liver, brain, heart, kidney

Anorexia

Increased energy metabolism (liver, muscle, adipose tissue) and lowered body weight

Stimulated thermogenic and lipolytic genes (BAT, WAT)

Improved glucose tolerance and insulin sensitivity

Prevented liver steatosis in HFD-fed mice

[84][85][86][87][88][89][90]

ANGPTL: Antiopoietin-like proteins; BAT: Brown adipose tissue; CNS: Central nervous system; FFA: Free fatty acid; FSH: Follicle-stimulating hormone; GDF15: Growth differentiation factor 15; HFD: High fat diet; LECT2: Leukocyte cell-derived chemotaxin 2; LPL: Lipoprotein lipase; RBP4: Retinol binding protein 4; SMOC1: SPARC-related modular calcium-binding protein 1; TG: Triglyceride; VLDL: Very low-density lipoprotein; WAT: White adipose tissue.

4. Hepatokines and NAFLD

It has been established that NAFLD is strongly associated with other metabolic comorbidities, including obesity, type 2 diabetes, dyslipidemia, cardiovascular disease, colonic diverticulosis, and neurodegenerative conditions [1][4][5][6][7][14][91]. Hepatic steatosis, which refers to a pathological state of the liver characterized by an accumulation of lipid content at over ~5% of the total organ weight, is closely associated with insulin resistance in multiple organs, as supported by several studies demonstrating impaired insulin action in both lean and non-diabetic obese individuals [14][92][93][94]. Moreover, hepatic steatosis usually develops prior to the accumulation of lipid in skeletal muscle, macrophage-driven inflammation, extrahepatic insulin resistance, and hyperglycemia [14][16][95], suggestive of its potential as an early indicator of systemic metabolic dysregulation. Interestingly, similar to adipose tissue or skeletal muscle where the secretion of respective organokines is altered via overnutrition, hepatic gene expression and protein content are also regulated in response to caloric overload, and these changes have been revealed to be strongly associated with the onset of insulin resistance and type 2 diabetes [26][96][97][98]. Many of the liver-secreted proteins that are upregulated in the plasma of subjects with type 2 diabetes were capable of inducing insulin resistance, supportive of the pathophysiological role of hepatokines in metabolic dysregulation [99]. Recent studies have provided valuable insight into the impact of ectopic fat accumulation in hepatocytes on alterations in the hepatic proteome, with suppressed protein synthesis observed in the livers of obese mice [100]. Furthermore, metabolic remodeling was mediated via changes in the translation/secretion processes or post-translational modifications, with minor changes at the transcriptional level [12][26]. In line with this notion, approximately 20% of proteins with an N-terminal signal peptide were differentially secreted from mouse steatotic hepatocytes compared to normal hepatocytes, and some of these proteins were found to induce insulin resistance and pro-inflammatory signaling [26]. The above-described findings indicate that a substantial fraction of the hepatic proteome is heavily distributed during NAFLD progression, which may significantly impair energy homeostasis and systemic metabolism. However, relatively a small number of hepatokines have been identified, with a few of their metabolic functions and related regulatory mechanism(s) in NAFLD progression investigated.

References

  1. Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298.
  2. Lee, Y.S.; Wollam, J.; Olefsky, J.M. An Integrated View of Immunometabolism. Cell 2018, 172, 22–40.
  3. Hotamisligil, G.S. Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542, 177–185.
  4. Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014, 2, 901–910.
  5. Younossi, Z.; Tacke, F.; Arrese, M.; Sharma, B.C.; Mostafa, I.; Bugianesi, E.; Wong, V.W.; Yilmaz, Y.; George, J.; Fan, J.; et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019, 69, 2672–2682.
  6. Younossi, Z.M. Non-alcoholic fatty liver disease–A global public health perspective. J. Hepatol. 2019, 70, 531–544.
  7. Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20.
  8. Adenote, A.; Dumic, I.; Madrid, C.; Barusya, C.; Nordstrom, C.W.; Rueda Prada, L. NAFLD and Infection, a Nuanced Relationship. Can. J. Gastroenterol. Hepatol. 2021, 2021, 5556354.
  9. Drucker, D.J. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: The end of the beginning. Cell Metab. 2021, 33, 479–498.
  10. Eslam, M.; Newsome, P.N.; Sarin, S.K.; Anstee, Q.M.; Targher, G.; Romero-Gomez, M.; Zelber-Sagi, S.; Wai-Sun Wong, V.; Dufour, J.; Schattenberg, J.M.; et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020, 73, 202–209.
  11. Eslam, M.; Sanyal, A.J.; George, J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020, 158, 1999–2014.
  12. Meex, R.C.R.; Watt, M.J. Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 2017, 13, 508–520.
  13. Stefan, N.; Häring, H. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013, 9, 144–152.
  14. Watt, M.J.; Miotto, P.M.; De Nardo, W.; Montgomery, M.K. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr. Rev. 2019, 40, 1367–1393.
  15. Jensen-Cody, S.O.; Potthoff, M.J. Hepatokines and metabolism: Deciphering communication from the liver. Mol. Metab. 2021, 44, 101138.
  16. Turner, N.; Kowalski, G.M.; Leslie, S.J.; Risis, S.; Yang, C.; Lee-Young, R.S.; Babb, J.R.; Meikle, P.J.; Lancaster, G.I.; Henstridge, D.C.; et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013, 56, 1638–1648.
  17. Samuel, V.T.; Liu, Z.; Qu, X.; Elder, B.D.; Bilz, S.; Befroy, D.; Romanelli, A.J.; Shulman, G.I. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004, 279, 32345–32353.
  18. Roden, M. Mechanisms of Disease: Hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2, 335–348.
  19. Ramnanan, C.J.; Saraswathi, V.; Smith, M.S.; Donahue, E.P.; Farmer, B.; Farmer, T.D.; Neal, D.; Williams, P.E.; Lautz, M.; Mari, A.; et al. Brain insulin action augments hepatic glycogen synthesis without suppressing glucose production or gluconeogenesis in dogs. J. Clin. Investig. 2011, 121, 3713–3723.
  20. Hodson, L.; Gunn, P.J. The regulation of hepatic fatty acid synthesis and partitioning: The effect of nutritional state. Nat. Rev. Endocrinol. 2019, 15, 689–700.
  21. Geisler, C.E.; Ghimire, S.; Bogan, R.L.; Renquist, B.J. Role of ketone signaling in the hepatic response to fasting. Am. J. Physiol. Gastrointest. Liver Physiol. 2019, 316, G623–G631.
  22. Kim, M.; Pinto, S.M.; Getnet, D.; Nirujogi, R.S.; Manda, S.S.; Chaerkady, R.; Madugundu, A.K.; Kelkar, D.S.; Isserlin, R.; Jain, S.; et al. A draft map of the human proteome. Nature 2014, 509, 575–581.
  23. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347, 1260419.
  24. Lai, K.K.Y.; Kolippakkam, D.; Beretta, L. Comprehensive and quantitative proteome profiling of the mouse liver and plasma. Hepatology 2008, 47, 1043–1051.
  25. Choi, K.M. The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis. Endocrinol. Metab. 2016, 31, 1–6.
  26. Meex, R.C.; Hoy, A.J.; Morris, A.; Brown, R.D.; Lo, J.C.Y.; Burke, M.; Goode, R.J.A.; Kingwell, B.A.; Kraakman, M.J.; Febbraio, M.A.; et al. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab. 2015, 22, 1078–1089.
  27. Dijk, W.; Kersten, S. Regulation of lipid metabolism by angiopoietin-like proteins. Curr. Opin. Lipidol. 2016, 27, 249–256.
  28. Kersten, S. Angiopoietin-like 3 in lipoprotein metabolism. Nat. Rev. Endocrinol. 2017, 13, 731–739.
  29. Chi, X.; Britt, E.C.; Shows, H.W.; Hjelmaas, A.J.; Shetty, S.K.; Cushing, E.M.; Li, W.; Dou, A.; Zhang, R.; Davies, B.S.J. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol. Metab. 2017, 6, 1137–1149.
  30. Kucukoglu, O.; Sowa, J.; Mazzolini, G.D.; Syn, W.; Canbay, A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J. Hepatol. 2021, 74, 442–457.
  31. Wang, Y.; McNutt, M.C.; Banfi, S.; Levin, M.G.; Holland, W.L.; Gusarova, V.; Gromada, J.; Cohen, J.C.; Hobbs, H.H. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc. Natl. Acad. Sci. USA 2015, 112, 11630–11635.
  32. Adam, R.C.; Mintah, I.J.; Alexa-Braun, C.A.; Shihanian, L.M.; Lee, J.S.; Banerjee, P.; Hamon, S.C.; Kim, H.I.; Cohen, J.C.; Hobbs, H.H.; et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J. Lipid Res. 2020, 61, 1271–1286.
  33. Wang, Y.; Gusarova, V.; Banfi, S.; Gromada, J.; Cohen, J.C.; Hobbs, H.H. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J. Lipid Res. 2015, 56, 1296–1307.
  34. Zhu, P.; Goh, Y.Y.; Chin, H.F.A.; Kersten, S.; Tan, N.S. Angiopoietin-like 4: A decade of research. Biosci. Rep. 2012, 32, 211–219.
  35. Yoshida, K.; Shimizugawa, T.; Ono, M.; Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 2002, 43, 1770–1772.
  36. Lichtenstein, L.; Berbée, J.F.P.; van Dijk, S.J.; van Dijk, K.W.; Bensadoun, A.; Kema, I.P.; Voshol, P.J.; Müller, M.; Rensen, P.C.N.; Kersten, S. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2420–2427.
  37. Sukonina, V.; Lookene, A.; Olivecrona, T.; Olivecrona, G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA 2006, 103, 17450–17455.
  38. McQueen, A.E.; Kanamaluru, D.; Yan, K.; Gray, N.E.; Wu, L.; Li, M.; Chang, A.; Hasan, A.; Stifler, D.; Koliwad, S.K.; et al. The C-terminal fibrinogen-like domain of angiopoietin-like 4 stimulates adipose tissue lipolysis and promotes energy expenditure. J. Biol. Chem. 2017, 292, 16122–16134.
  39. Xu, A.; Lam, M.C.; Chan, K.W.; Wang, Y.; Zhang, J.; Hoo, R.L.C.; Xu, J.Y.; Chen, B.; Chow, W.; Tso, A.W.K.; et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci. USA 2005, 102, 6086–6091.
  40. Hato, T.; Tabata, M.; Oike, Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc. Med. 2008, 18, 6–14.
  41. Qaddoumi, M.G.; Alanbaei, M.; Hammad, M.M.; Al Khairi, I.; Cherian, P.; Channanath, A.; Thanaraj, T.A.; Al-Mulla, F.; Abu-Farha, M.; Abubaker, J. Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes. Sci. Rep. 2020, 10, 6170.
  42. Kitazawa, M.; Ohizumi, Y.; Oike, Y.; Hishinuma, T.; Hashimoto, S. Angiopoietin-related growth factor suppresses gluconeogenesis through the Akt/forkhead box class O1-dependent pathway in hepatocytes. J. Pharmacol. Exp. Ther. 2007, 323, 787–793.
  43. Kang, S.G.; Yi, H.; Choi, M.J.; Ryu, M.J.; Jung, S.; Chung, H.K.; Chang, J.Y.; Kim, Y.K.; Lee, S.E.; Kim, H.; et al. ANGPTL6 expression is coupled with mitochondrial OXPHOS function to regulate adipose FGF21. J. Endocrinol. 2017, 233, 105–118.
  44. Abu-Farha, M.; Ghosh, A.; Al-Khairi, I.; Madiraju, S.R.M.; Abubaker, J.; Prentki, M. The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation. Prog. Lipid Res. 2020, 80, 101067.
  45. Zhang, R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem. Biophys. Res. Commun. 2012, 424, 786–792.
  46. Zhang, Y.; Li, S.; Donelan, W.; Xie, C.; Wang, H.; Wu, Q.; Purich, D.L.; Reeves, W.H.; Tang, D.; Yang, L. Angiopoietin-like protein 8 (betatrophin) is a stress-response protein that down-regulates expression of adipocyte triglyceride lipase. Biochim. Biophys. Acta 2016, 1861, 130–137.
  47. Zhang, Z.; Wu, H.; Dai, L.; Yuan, Y.; Zhu, Y.; Ma, Z.; Ruan, X.; Guo, X. ANGPTL8 enhances insulin sensitivity by directly activating insulin-mediated AKT phosphorylation. Gene 2020, 749, 144707.
  48. Nidhina Haridas, P.A.; Soronen, J.; Sädevirta, S.; Mysore, R.; Quagliarini, F.; Pasternack, A.; Metso, J.; Perttilä, J.; Leivonen, M.; Smas, C.M.; et al. Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin. J. Clin. Endocrinol. Metab. 2015, 100, 1299.
  49. Goustin, A.; Abou-Samra, A.B. The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal 2011, 23, 980–990.
  50. Mathews, S.T.; Chellam, N.; Srinivas, P.R.; Cintron, V.J.; Leon, M.A.; Goustin, A.S.; Grunberger, G. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol. Cell Endocrinol. 2000, 164, 87–98.
  51. Auberger, P.; Falquerho, L.; Contreres, J.O.; Pages, G.; Le Cam, G.; Rossi, B.; Le Cam, A. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989, 58, 631–640.
  52. Mathews, S.T.; Singh, G.P.; Ranalletta, M.; Cintron, V.J.; Qiang, X.; Goustin, A.S.; Jen, K.C.; Charron, M.J.; Jahnen-Dechent, W.; Grunberger, G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002, 51, 2450–2458.
  53. Mukhopadhyay, S.; Bhattacharya, S. Plasma fetuin-A triggers inflammatory changes in macrophages and adipocytes by acting as an adaptor protein between NEFA and TLR-4. Diabetologia 2016, 59, 859–860.
  54. Pal, D.; Dasgupta, S.; Kundu, R.; Maitra, S.; Das, G.; Mukhopadhyay, S.; Ray, S.; Majumdar, S.S.; Bhattacharya, S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 2012, 18, 1279–1285.
  55. Stefan, N.; Häring, H. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat. Med. 2013, 19, 394–395.
  56. Zhou, W.; Yang, J.; Zhu, J.; Wang, Y.; Wu, Y.; Xu, L.; Yang, Y. Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice. Am. J. Transl. Res. 2019, 11, 1498–1509.
  57. Fon Tacer, K.; Bookout, A.L.; Ding, X.; Kurosu, H.; John, G.B.; Wang, L.; Goetz, R.; Mohammadi, M.; Kuro-o, M.; Mangelsdorf, D.J.; et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 2010, 24, 2050–2064.
  58. Xu, J.; Lloyd, D.J.; Hale, C.; Stanislaus, S.; Chen, M.; Sivits, G.; Vonderfecht, S.; Hecht, R.; Li, Y.; Lindberg, R.A.; et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58, 250–259.
  59. Berglund, E.D.; Li, C.Y.; Bina, H.A.; Lynes, S.E.; Michael, M.D.; Shanafelt, A.B.; Kharitonenkov, A.; Wasserman, D.H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150, 4084–4093.
  60. Coskun, T.; Bina, H.A.; Schneider, M.A.; Dunbar, J.D.; Hu, C.C.; Chen, Y.; Moller, D.E.; Kharitonenkov, A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149, 6018–6027.
  61. Misu, H.; Takamura, T.; Takayama, H.; Hayashi, H.; Matsuzawa-Nagata, N.; Kurita, S.; Ishikura, K.; Ando, H.; Takeshita, Y.; Ota, T.; et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010, 12, 483–495.
  62. Zeng, M.; Li, X.; Liu, Y.; Zhao, H.; Zhou, J.; Li, K.; Huang, J.; Sun, L.; Tang, J.; Xia, X.; et al. A high-selenium diet induces insulin resistance in gestating rats and their offspring. Free Radic. Biol. Med. 2012, 52, 1335–1342.
  63. Hellwege, J.N.; Palmer, N.D.; Ziegler, J.T.; Langefeld, C.D.; Lorenzo, C.; Norris, J.M.; Takamura, T.; Bowden, D.W. Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics. Gene 2014, 534, 33–39.
  64. Ko, B.J.; Kim, S.M.; Park, K.H.; Park, H.S.; Mantzoros, C.S. Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children. Int. J. Obes. 2014, 38, 1497–1502.
  65. Lan, F.; Misu, H.; Chikamoto, K.; Takayama, H.; Kikuchi, A.; Mohri, K.; Takata, N.; Hayashi, H.; Matsuzawa-Nagata, N.; Takeshita, Y.; et al. LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. Diabetes 2014, 63, 1649–1664.
  66. Takata, N.; Ishii, K.; Takayama, H.; Nagashimada, M.; Kamoshita, K.; Tanaka, T.; Kikuchi, A.; Takeshita, Y.; Matsumoto, Y.; Ota, T.; et al. LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Sci. Rep. 2021, 11, 555.
  67. Ueno, N.; Ling, N.; Ying, S.Y.; Esch, F.; Shimasaki, S.; Guillemin, R. Isolation and partial characterization of follistatin: A single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc. Natl. Acad. Sci. USA 1987, 84, 8282–8286.
  68. Tao, R.; Wang, C.; Stöhr, O.; Qiu, W.; Hu, Y.; Miao, J.; Dong, X.C.; Leng, S.; Stefater, M.; Stylopoulos, N.; et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat. Med. 2018, 24, 1058–1069.
  69. Wu, H.; Ballantyne, C.M. Skeletal muscle inflammation and insulin resistance in obesity. J. Clin. Investig. 2017, 127, 43–54.
  70. Braga, M.; Reddy, S.T.; Vergnes, L.; Pervin, S.; Grijalva, V.; Stout, D.; David, J.; Li, X.; Tomasian, V.; Reid, C.B.; et al. Follistatin promotes adipocyte differentiation, browning, and energy metabolism. J. Lipid Res. 2014, 55, 375–384.
  71. Singh, R.; Braga, M.; Reddy, S.T.; Lee, S.; Parveen, M.; Grijalva, V.; Vergnes, L.; Pervin, S. Follistatin Targets Distinct Pathways to Promote Brown Adipocyte Characteristics in Brown and White Adipose Tissues. Endocrinology 2017, 158, 1217–1230.
  72. Wu, H.; Ou, H.; Hung, H.; Su, Y.; Lu, F.; Wu, J.; Yang, Y.; Wu, C.; Chang, C. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia 2016, 59, 1732–1742.
  73. Jung, T.W.; Chung, Y.H.; Kim, H.; Abd El-Aty, A.M.; Jeong, J.H. Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle. Mol. Cell. Endocrinol. 2018, 470, 26–33.
  74. Wu, H.; Lu, F.; Ou, H.; Su, Y.; Hung, H.; Wu, J.; Yang, Y.; Wu, C.; Chang, C. The role of hepassocin in the development of non-alcoholic fatty liver disease. J. Hepatol. 2013, 59, 1065–1072.
  75. Wu, H.; Chen, S.; Fan, K.; Kuo, C.; Lin, S.; Wang, S.; Chang, C.; Li, H. Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity. FASEB J. 2020, 34, 2958–2967.
  76. Kilicarslan, M.; de Weijer, B.A.; Simonyté Sjödin, K.; Aryal, P.; Ter Horst, K.W.; Cakir, H.; Romijn, J.A.; Ackermans, M.T.; Janssen, I.M.; Berends, F.J.; et al. RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women. FASEB J. 2020, 34, 6099–6110.
  77. Graham, T.E.; Yang, Q.; Blüher, M.; Hammarstedt, A.; Ciaraldi, T.P.; Henry, R.R.; Wason, C.J.; Oberbach, A.; Jansson, P.; Smith, U.; et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 2006, 354, 2552–2563.
  78. Liu, Y.; Mu, D.; Chen, H.; Li, D.; Song, J.; Zhong, Y.; Xia, M. Retinol-Binding Protein 4 Induces Hepatic Mitochondrial Dysfunction and Promotes Hepatic Steatosis. J. Clin. Endocrinol. Metab. 2016, 101, 4338–4348.
  79. Yang, Q.; Graham, T.E.; Mody, N.; Preitner, F.; Peroni, O.D.; Zabolotny, J.M.; Kotani, K.; Quadro, L.; Kahn, B.B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436, 356–362.
  80. Norseen, J.; Hosooka, T.; Hammarstedt, A.; Yore, M.M.; Kant, S.; Aryal, P.; Kiernan, U.A.; Phillips, D.A.; Maruyama, H.; Kraus, B.J.; et al. Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol. Cell. Biol. 2012, 32, 2010–2019.
  81. Moraes-Vieira, P.M.; Yore, M.M.; Dwyer, P.M.; Syed, I.; Aryal, P.; Kahn, B.B. RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell. Metab. 2014, 19, 512–526.
  82. Fedders, R.; Muenzner, M.; Weber, P.; Sommerfeld, M.; Knauer, M.; Kedziora, S.; Kast, N.; Heidenreich, S.; Raila, J.; Weger, S.; et al. Liver-secreted RBP4 does not impair glucose homeostasis in mice. J. Biol. Chem. 2018, 293, 15269–15276.
  83. Montgomery, M.K.; Bayliss, J.; Devereux, C.; Bezawork-Geleta, A.; Roberts, D.; Huang, C.; Schittenhelm, R.B.; Ryan, A.; Townley, S.L.; Selth, L.A.; et al. SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Sci. Transl. Med. 2020, 12, eaaz8048.
  84. Baek, S.J.; Eling, T. Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases. Pharmacol. Ther. 2019, 198, 46–58.
  85. Chrysovergis, K.; Wang, X.; Kosak, J.; Lee, S.H.; Kim, J.S.; Foley, J.F.; Travlos, G.; Singh, S.; Baek, S.J.; Eling, T.E. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int. J. Obes. 2014, 38, 1555–1564.
  86. Chung, H.K.; Ryu, D.; Kim, K.S.; Chang, J.Y.; Kim, Y.K.; Yi, H.; Kang, S.G.; Choi, M.J.; Lee, S.E.; Jung, S.; et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J. Cell Biol. 2017, 216, 149–165.
  87. Mullican, S.E.; Lin-Schmidt, X.; Chin, C.; Chavez, J.A.; Furman, J.L.; Armstrong, A.A.; Beck, S.C.; South, V.J.; Dinh, T.Q.; Cash-Mason, T.D.; et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 2017, 23, 1150–1157.
  88. Yang, L.; Chang, C.; Sun, Z.; Madsen, D.; Zhu, H.; Padkjær, S.B.; Wu, X.; Huang, T.; Hultman, K.; Paulsen, S.J.; et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 2017, 23, 1158–1166.
  89. Hsu, J.; Crawley, S.; Chen, M.; Ayupova, D.A.; Lindhout, D.A.; Higbee, J.; Kutach, A.; Joo, W.; Gao, Z.; Fu, D.; et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 2017, 550, 255–259.
  90. Borner, T.; Shaulson, E.D.; Ghidewon, M.Y.; Barnett, A.B.; Horn, C.C.; Doyle, R.P.; Grill, H.J.; Hayes, M.R.; De Jonghe, B.C. GDF15 Induces Anorexia through Nausea and Emesis. Cell. Metab. 2020, 31, 351–362.
  91. Milovanovic, T.; Pantic, I.; Dragasevic, S.; Lugonja, S.; Dumic, I.; Rajilic-Stojanovic, M. The Interrelationship among Non-Alcoholic Fatty Liver Disease, Colonic Diverticulosis and Metabolic Syndrome. J. Gastrointest. Liver Dis. 2021, 30, 274–282.
  92. Seppälä-Lindroos, A.; Vehkavaara, S.; Häkkinen, A.; Goto, T.; Westerbacka, J.; Sovijärvi, A.; Halavaara, J.; Yki-Järvinen, H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 2002, 87, 3023–3028.
  93. Korenblat, K.M.; Fabbrini, E.; Mohammed, B.S.; Klein, S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134, 1369–1375.
  94. Bugianesi, E.; Gastaldelli, A.; Vanni, E.; Gambino, R.; Cassader, M.; Baldi, S.; Ponti, V.; Pagano, G.; Ferrannini, E.; Rizzetto, M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005, 48, 634–642.
  95. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 2003, 112, 1821–1830.
  96. Kirpich, I.A.; Gobejishvili, L.N.; Bon Homme, M.; Waigel, S.; Cave, M.; Arteel, G.; Barve, S.S.; McClain, C.J.; Deaciuc, I.V. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem. 2011, 22, 38–45.
  97. Zhang, X.; Yang, J.; Guo, Y.; Ye, H.; Yu, C.; Xu, C.; Xu, L.; Wu, S.; Sun, W.; Wei, H.; et al. Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: Enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 2010, 51, 1190–1199.
  98. Younossi, Z.M.; Baranova, A.; Ziegler, K.; Del Giacco, L.; Schlauch, K.; Born, T.L.; Elariny, H.; Gorreta, F.; VanMeter, A.; Younoszai, A.; et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42, 665–674.
  99. Kaur, P.; Rizk, N.M.; Ibrahim, S.; Younes, N.; Uppal, A.; Dennis, K.; Karve, T.; Blakeslee, K.; Kwagyan, J.; Zirie, M.; et al. iTRAQ-based quantitative protein expression profiling and MRM verification of markers in type 2 diabetes. J. Proteome Res. 2012, 11, 5527–5539.
  100. Fu, S.; Fan, J.; Blanco, J.; Gimenez-Cassina, A.; Danial, N.N.; Watkins, S.M.; Hotamisligil, G.S. Polysome profiling in liver identifies dynamic regulation of endoplasmic reticulum translatome by obesity and fasting. PLoS Genet. 2012, 8, e1002902.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Endocrinology & Metabolism
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Yoon Mee Yang
View Times: 626
Revisions: 2 times (View History)
Update Date: 21 Dec 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Academic Video Service
    Feedback